Ongoing trials:

Principal Investigator: “ALXN-MG-501, Long-Term, Observational, Registry of Patients with Generalized Myasthenia Gravis Who Have Received Treatment with Complement C5 Inhibition Therapies”

Principal Investigator: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy

Principal Investigator: A Phase 4, Open label, Prospective, Single Group, Multicenter Study to Evaluate the Clinical Outcomes of Egfartigimod PH20 SC in Adult Participants with New Onset Generalized Myasthenia Gravis
Principal Investigator: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients with Mild to Severe Generalized Myasthenia Gravis

Principal Investigator: A Global Real-World Study to Assess HyQvia Use and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Switching to HyQvia

Principal Investigator: A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Principal Investigator: A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of empasiprubart versus Intravenous Immunoglobulin (IVIg) in Adults with Multifocal Motor Neuropathy

Principal Investigator: A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Principal Investigator: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Principal Investigator: A Multicenter Prospective Longitudinal Study of Clinical Outcomes, Disease Course, Health-Related Quality of Life, and Health Care Resource Utilization in Adult Patients with Multifocal Motor Neuropathy

Principal Investigator: An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants with Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Completed trials:

Principal Investigator: DDF, “IVIG in Dysimmune Inflammatory Neuropathy (DIN) with/without Diabetes Mellitus (DM)”

Principal Investigator: ADHERE: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)

Principal Investigator: ADHERE+: Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Principal Investigator: MG 0017: An open-label study to evaluate the safety, tolerability, and efficacy of subcutaneous zilucoplan in participants with generalized myasthenia gravis who were previously receiving intravenous complement component 5 inhibitors

Study Coordinator (2004/05): “A randomized, double-blind, parallel group, placebo-controlled, single-attack evaluation of the efficacy and tolerability of Trexima (sumatriptan 85mg/naproxen sodium 500mg) tablets vs. placebo when administered during the mild phase of migraine”

University of Kansas Medical Center Research Day presentation (06/08): Case series of 11 patients of Primary Progressive Aphasia

University of Kansas Medical Center Research Day Presentation (06/09): Case series of 6 patients of myeloneuropathy due to copper deficiency

Publications:

Efficacy of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy with or without diabetes: insights from a multicenter prospective comparative study. Macwan SP, Mahajan S, Novak P, Farhad K, Wong E, Brannagan TH, Masood S, Piracha F, Dalakas MC. Ther Adv Neurol Disord. 2025 Dec 21; 18:17562864251401496. Doi: 10.1177/1756864251401496. eCollection 2025. PMID: 41446323.

Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.
Freimer M, Desai U, Govindarajan R, Kang MK, Khan S, Khatri B, Levine T, Macwan S, Shieh PB, Weiss MD, Bloemers J, Boroojerdi B, Delicha EM, Lavrov A, Singh P, Howard JF Jr.Ther Adv Neurol Disord. 2025 Jul 5;18:17562864251347283. doi: 10.1177/17562864251347283. eCollection 2025.

Sahai S, Macwan S. Atypical Facial Neuralgia. Journal of Practical Pain Management. Nov/Dec 2004; 4(6): 49-52.

Dang T, Macwan S, Dasanu C, Late-onset double seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use of Hodgkin’s lymphoma. Journal of Oncol Pharm Pract. 2020; 1177

The Mighty’s Lambert-Eaton Myasthenic Syndrome (LEMS) Condition Guide
The Mighty • October 1st, 2021
Medically reviewed by Dr. Samir Macwan, M.D.